GoKawiilStudy describes drug approach that degrades cancer kinases instead of just blocking them
Researchers led by Conery et al., writing in Nature, report a strategy for treating lung cancers driven by mutated kinase enzymes that destroys the target protein entirely rather than merely inhibiting its activity. The approach is aimed at cancers that develop resistance to existing kinase inhibitors after acquiring mutations near the drug's binding site. Twenty-eight kinase inhibitors are already FDA-approved across nine molecular lung cancer subtypes, but many patients eventually relapse due to such resistance mutations.
GoKawiil's interpretation of the reporting above, not reported fact.
Because resistance mutations often arise at or near the kinase's active site, drugs designed to inhibit that site can lose effectiveness over time; eliminating the protein altogether could sidestep this problem regardless of where a resistance mutation occurs. This suggests degrader-based therapies might offer a more durable treatment option for relapsed patients, though the commentary notes this is described as a new approach rather than a proven clinical outcome.
- 28 FDA-approved kinase inhibitors currently treat nine molecular subtypes of lung cancer
- Drug resistance commonly develops from mutations near the kinase's active site
- New research proposes degrading the cancer-driving kinase protein instead of only inhibiting it
Source: nature.com — Shaw, 2026-09-29
Published there as: “A new chapter in targeting kinase enzymes in cancer”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.